Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis

托法替尼 医学 类风湿性关节炎 内科学 癌症 肿瘤科 皮肤病科
作者
Steven R. Ytterberg,Deepak L. Bhatt,Ted R. Mikuls,Gary G. Koch,Roy Fleischmann,Jose L. Rivas,Rebecca Germino,Sujatha S. Menon,Yanhui Sun,Cunshan Wang,Andrea B. Shapiro,Keith S. Kanik,Carol A. Connell
出处
期刊:The New England Journal of Medicine [Massachusetts Medical Society]
卷期号:386 (4): 316-326 被引量:1954
标识
DOI:10.1056/nejmoa2109927
摘要

BACKGROUND: Increases in lipid levels and cancers with tofacitinib prompted a trial of major adverse cardiovascular events (MACE) and cancers in patients with rheumatoid arthritis receiving tofacitinib as compared with a tumor necrosis factor (TNF) inhibitor. METHODS: We conducted a randomized, open-label, noninferiority, postauthorization, safety end-point trial involving patients with active rheumatoid arthritis despite methotrexate treatment who were 50 years of age or older and had at least one additional cardiovascular risk factor. Patients were randomly assigned in a 1:1:1 ratio to receive tofacitinib at a dose of 5 mg or 10 mg twice daily or a TNF inhibitor. The coprimary end points were adjudicated MACE and cancers, excluding nonmelanoma skin cancer. The noninferiority of tofacitinib would be shown if the upper boundary of the two-sided 95% confidence interval for the hazard ratio was less than 1.8 for the combined tofacitinib doses as compared with a TNF inhibitor. RESULTS: A total of 1455 patients received tofacitinib at a dose of 5 mg twice daily, 1456 received tofacitinib at a dose of 10 mg twice daily, and 1451 received a TNF inhibitor. During a median follow-up of 4.0 years, the incidences of MACE and cancer were higher with the combined tofacitinib doses (3.4% [98 patients] and 4.2% [122 patients], respectively) than with a TNF inhibitor (2.5% [37 patients] and 2.9% [42 patients]). The hazard ratios were 1.33 (95% confidence interval [CI], 0.91 to 1.94) for MACE and 1.48 (95% CI, 1.04 to 2.09) for cancers; the noninferiority of tofacitinib was not shown. The incidences of adjudicated opportunistic infections (including herpes zoster and tuberculosis), all herpes zoster (nonserious and serious), and adjudicated nonmelanoma skin cancer were higher with tofacitinib than with a TNF inhibitor. Efficacy was similar in all three groups, with improvements from month 2 that were sustained through trial completion. CONCLUSIONS: In this trial comparing the combined tofacitinib doses with a TNF inhibitor in a cardiovascular risk-enriched population, risks of MACE and cancers were higher with tofacitinib and did not meet noninferiority criteria. Several adverse events were more common with tofacitinib. (Funded by Pfizer; ORAL Surveillance ClinicalTrials.gov number, NCT02092467.).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
霸气的小天鹅完成签到,获得积分10
刚刚
Tree完成签到 ,获得积分10
1秒前
别忘了吃胶囊完成签到,获得积分10
1秒前
科研通AI6.2的应助被healer采纳,获得10
3秒前
大个的应助被tyche采纳,获得10
3秒前
coco完成签到 ,获得积分10
3秒前
嘻嘻哈哈发布了新的文献求助280
4秒前
ggdh发布了新的文献求助10
4秒前
4秒前
5秒前
莫断痕的应助被ax采纳,获得10
5秒前
生动的保温杯完成签到,获得积分10
5秒前
天天快乐的应助被蓝斯登采纳,获得10
6秒前
gnufgg完成签到,获得积分10
7秒前
小面包发布了新的文献求助20
7秒前
勤奋一一的应助被飞行的鸡翅采纳,获得10
7秒前
7秒前
8秒前
8秒前
李宁文完成签到,获得积分10
9秒前
honor发布了新的文献求助10
9秒前
9秒前
nca12345关注了科研通微信公众号
10秒前
FYSYYC发布了新的文献求助10
10秒前
无情鹏煊完成签到,获得积分10
10秒前
liyang发布了新的文献求助10
11秒前
FERNWEH发布了新的文献求助10
11秒前
qianyu完成签到,获得积分10
11秒前
13秒前
13秒前
McbxM发布了新的文献求助10
14秒前
yunkong完成签到,获得积分10
14秒前
可爱的函函的应助被小李子采纳,获得10
15秒前
同学的店完成签到,获得积分10
16秒前
斜月吟风完成签到 ,获得积分10
16秒前
16秒前
Zyy完成签到 ,获得积分10
16秒前
song完成签到 ,获得积分0
17秒前
18秒前
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8168163
求助须知:如何正确求助?哪些是违规求助? 9561243
关于积分的说明 21759855
捐赠科研通 7759477
什么是DOI,文献DOI怎么找? 3429959
关于科研通互助平台的介绍 2553757
邀请新用户注册赠送积分活动 2474496